Rodabe N. Amaria, MD, explains a trial of OBX-115, a novel engineered tumor infiltrating lymphocyte therapy, in checkpoint ...

During a live event, Sumanta K. Pal, MD, discusses the efficacy and safety findings from the CheckMate 274 trial of adjuvant ...

Panelists discuss treatment decision-making for metastatic non–-small cell lung cancer (NSCLC) with a ROS1 alteration, ...

During a live event, Thach-Giao Truong, MD, moderated a discussion on treating a 78-year-old patient with metastatic melanoma ...

Georgina V. Long, MD, MSc, discussed the long-term follow-up data for the combination of adjuvant dabrafenib and trametinib ...

The FDA granted orphan drug designation to HLX22 for gastric cancer, advancing global phase 3 trials to improve first-line ...

A phase 3 trial plans to evaluate Pro-ocular for the treatment of patients with ocular graft-vs-host disease. Signal12 ...

An expert discusses how the availability of subcutaneous (SC) immune checkpoint inhibitors (ICI) for bladder cancer impacts ...

An expert discusses how medical professionals monitor and manage adverse events (AEs) with adjuvant nivolumab through regular ...

An expert discusses how medical professionals are increasingly utilizing circulating tumor DNA (ctDNA) and tissue PD-L1 to ...

An expert discusses how medical professionals counsel eligible patients about adjuvant immune checkpoint inhibitor (ICI) ...

Toon Van Gorp, MD, PhD, discussed findings from the MIRASOL trial and the potential of mirvetuximab to redefine treatment ...